Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
May act as a specific coactivator for the mammalian TEFs (By similarity).. Additionally we are shipping Vestigial Like 4 (Drosophila) Proteins (5) and and many more products for this protein.
Showing 10 out of 51 products:
Human Polyclonal VGLL4 Primary Antibody for WB - ABIN1881992
Chen, Mullett, Stewart: Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes. in The Journal of biological chemistry 2004
Show all 2 Pubmed References
Human Polyclonal VGLL4 Primary Antibody for ICC, IF - ABIN4365266
Stadler, Rexhepaj, Singan, Murphy, Pepperkok, Uhlén, Simpson, Lundberg: Immunofluorescence and fluorescent-protein tagging show high correlation for protein localization in mammalian cells. in Nature methods 2013
Results identify VGLL4 as a direct target gene of miR (show MLXIP Antibodies)-130b in Bladder cancer (BCa (show BLNK Antibodies)) cells. Its suppression is crucial for miR (show MLXIP Antibodies)-130b-induced BCa (show BLNK Antibodies) cell proliferation, migration and invasion.
The Vgll4 is phosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1 (show CDK1 Antibodies)) during antimitotic drug-induced mitotic arrest and also in normal mitosis.
VGLL4 - novel candidate genes validated in a large case-control sample of schizophrenia.
The expression level of VGLL4 protein was down-regulated in gastric cancer tissues.VGLL4 inhibits epithelial-mesenchymal transition in part through suppressing Wnt (show WNT2 Antibodies)-beta-catenin (show CTNNB1 Antibodies) signaling pathway in gastric cancer.
our study suggested that downregulation of VGLL4 was very important in the progression of ESCC, and restoring the function of VGLL4 might be a promising therapeutic strategy for ESCC.
VGLL4 directly competes with YAP (show YAP1 Antibodies) in binding to TEADs and executes its growth-inhibitory function through two TDU (show VGLL1 Antibodies) domains.
rs2616551 in VGLL4 was found to be nominally associated with anorexia nervosa.
This study introduces a novel gain-of-function approach for studying hESC maintenance and presents VGLL4 as a previously undescribed regulator of this process.
Loss of VGLL4 expression is associated with gastric cancer.
Vgl-4 may play a role in the apoptotic pathways by regulating translocation of IAPs between different cell compartments.
VGLL4 inhibits cardiomyocyte proliferation by inhibiting TEAD1 (show TEAD1 Antibodies)-YAP (show YAP1 Antibodies) interaction and by targeting TEAD1 (show TEAD1 Antibodies) for degradation.
Vgl-4 modulates the activity of TEF-1 (show TEAD1 Antibodies) factors and counteracts alpha1-adrenergic activation of gene expression in cardiac myocytes
May act as a specific coactivator for the mammalian TEFs (By similarity).
transcription cofactor vestigial-like protein 4
, Vestigial-like 4